Page last updated: 2024-12-11

plastoquinone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5375177
CHEBI ID28377
SCHEMBL ID323746
MeSH IDM0017007

Synonyms (30)

Synonym
PQA ,
plastoquinone ,
plastoquinone-9 ,
plastoquinone a
4299-57-4
2,3-dimethyl-5-[(2e,6e,10e,14e,18e,22e,26e,30e)-3,7,11,15,19,23,27,31,35-nonamethylhexatriaconta-2,6,10,14,18,22,26,30,34-nonaenyl]cyclohexa-2,5-diene-1,4-dione
CHEBI:28377
2,3-dimethyl-5-(solanesyl)-1,4-benzoquinone
plastoquinone 45
2,3-dimethyl-5-[(2e,6e,10e,14e,18e,22e,26e,30e)-3,7,11,15,19,23,27,31,35-nonamethylhexatriaconta-2,6,10,14,18,22,26,30,34-nonaen-1-yl]cyclohexa-2,5-diene-1,4-dione
pq-9
kofler's quinone
(all-e)-2,3-dimethyl-5-(3,7,11,15,19,23,27,31,35-nonamethyl-2,6,10,14,18,22,26,30,34-hexatricontanonaenyl)-2,5-cyclohexadiene-1-4-dione
2,5-cyclohexadiene-1,4-dione, 2,3-dimethyl-5-(3,7,11,15,19,23,27,31,35-nonamethyl-2,6,10,14,18,22,26,30,34-hexatriacontanonaenyl)-, (all-e)-
koflers quinone
koflerquinone 45
q 254
oac30j69cn ,
unii-oac30j69cn
q-254
2,5-cyclohexadiene-1,4-dione, 2,3-dimethyl-5-((2e,6e,10e,14e,18e,22e,26e,30e)-3,7,11,15,19,23,27,31,35-nonamethyl-2,6,10,14,18,22,26,30,34-hexatriacontanonaen-1-yl)-
plastoquinone 9 [mi]
SCHEMBL323746
FKUYMLZIRPABFK-IQSNHBBHSA-N
2,3-dimethyl-5-[(2e,6e,10e,14e,18e,22e,26e,30e)-3,7,11,15,19,23,27,31,35-nonamethyl-2,6,10,14,18,22,26,30,34-hexatriacontanonaenyl]benzo-1,4-quinone #
p-benzoquinone, 2,3-dimethyl-5-(3,7,11,15,19,23,27,31,35-nonamethyl-2,6,10,14,18,22,26,30,34-hexatriacontanonaenyl)-, (all e)-
2,5-cyclohexadiene-1,4-dione, 2,3-dimethyl-5-(3,7,11,15,19,23,27,31,35-nonamethyl-2,6,10,14,18,22,26,30,34-hexatriacontanonaenyl)-
DTXSID40893791
Q31887279
AKOS040753577

Research Excerpts

Overview

Plastoquinone-9 (PQ-9) is an essential component of photosynthesis. It carries electrons in the linear and alternative electron transport chains. It is also a redox sensor that regulates state transitions and gene expression.

ExcerptReferenceRelevance
"Plastoquinone-9 (PQ-9) is an essential component of photosynthesis that carries electrons in the linear and alternative electron transport chains, and is also a redox sensor that regulates state transitions and gene expression. "( Plastoquinone In and Beyond Photosynthesis.
Havaux, M, 2020
)
3.44
"Plastoquinone is a redox active lipid that serves as electron transporter in the bifunctional photosynthetic-respiratory transport chain of cyanobacteria. "( Chorismate pyruvate-lyase and 4-hydroxy-3-solanesylbenzoate decarboxylase are required for plastoquinone biosynthesis in the cyanobacterium Synechocystis sp. PCC6803.
Frentzen, M; Glindemann, N; Gruber, J; Pfaff, C; Sadre, R, 2014
)
2.07
"The plastoquinone (PQ) pool acts as a common electron carrier in these pathways."( Redox state of the photosynthetic electron transport chain in wild-type and mutant leaves of Arabidopsis thaliana: Impact on photosystem II fluorescence.
Carpentier, R; Jemâa, E; Joly, D, 2010
)
0.84

Actions

ExcerptReferenceRelevance
"Plastoquinone plays critical roles in photosynthesis, chlororespiration and carotenoid biosynthesis. "( The pds2 mutation is a lesion in the Arabidopsis homogentisate solanesyltransferase gene involved in plastoquinone biosynthesis.
DellaPenna, D; Dixon, RA; Tian, L, 2007
)
2

Toxicity

ExcerptReferenceRelevance
" Safety measures included adverse events, slit lamp biomicroscopy, tonometry, blood pressure, and heart rate."( Results of a Multicenter, Randomized, Double-Masked, Placebo-Controlled Clinical Study of the Efficacy and Safety of Visomitin Eye Drops in Patients with Dry Eye Syndrome.
Alekseev, VN; Andryukhina, OM; Bezditko, PA; Brzheskiy, VV; Efimova, EL; Egorov, EA; Fedorkin, ON; Gusarevich, OG; Kamenskikh, TG; Karger, EM; Korol, AR; Lebedev, OI; Miljudin, ES; Mironov, AN; Muzhychuk, OP; Nasinnyk, IO; Ostapenko, V; Popeko, NA; Ryabtseva, AA; Savchenko, AY; Shaidurova, KN; Skulachev, MV; Skulachev, VP; Sumarokova, ES; Surov, AV; Vorontsova, TN; Vygodin, VA; Yani, EV, 2015
)
0.42
"Based on the results of this study, Visomitin is effective and safe for use in eye patients with DES for protection from corneal damage."( Results of a Multicenter, Randomized, Double-Masked, Placebo-Controlled Clinical Study of the Efficacy and Safety of Visomitin Eye Drops in Patients with Dry Eye Syndrome.
Alekseev, VN; Andryukhina, OM; Bezditko, PA; Brzheskiy, VV; Efimova, EL; Egorov, EA; Fedorkin, ON; Gusarevich, OG; Kamenskikh, TG; Karger, EM; Korol, AR; Lebedev, OI; Miljudin, ES; Mironov, AN; Muzhychuk, OP; Nasinnyk, IO; Ostapenko, V; Popeko, NA; Ryabtseva, AA; Savchenko, AY; Shaidurova, KN; Skulachev, MV; Skulachev, VP; Sumarokova, ES; Surov, AV; Vorontsova, TN; Vygodin, VA; Yani, EV, 2015
)
0.42
" Subjects were exposed to a controlled adverse environment chamber at 3 of the 4 study visits (Day -7, Day 1, and Day 29)."( SkQ1 Ophthalmic Solution for Dry Eye Treatment: Results of a Phase 2 Safety and Efficacy Clinical Study in the Environment and During Challenge in the Controlled Adverse Environment Model.
Ousler, G; Perekhvatova, N; Petrov, A; Skulachev, M; Stein, L, 2016
)
0.43
"SkQ1 was safe and efficacious in treating dry eye signs and symptoms."( SkQ1 Ophthalmic Solution for Dry Eye Treatment: Results of a Phase 2 Safety and Efficacy Clinical Study in the Environment and During Challenge in the Controlled Adverse Environment Model.
Ousler, G; Perekhvatova, N; Petrov, A; Skulachev, M; Stein, L, 2016
)
0.43
"This Phase 2 study indicated that SkQ1 is safe and efficacious for the treatment of dry eye signs and symptoms and supported previous study results."( SkQ1 Ophthalmic Solution for Dry Eye Treatment: Results of a Phase 2 Safety and Efficacy Clinical Study in the Environment and During Challenge in the Controlled Adverse Environment Model.
Ousler, G; Perekhvatova, N; Petrov, A; Skulachev, M; Stein, L, 2016
)
0.43

Dosage Studied

ExcerptRelevanceReference
"We investigated the dose-response relationship of MitoQ, SKQ1, and vitamin C on Dox-induced damage on H9c2 cardiomyoblasts when drugs were given concurrently with Dox (e."( Mitochondrial targeted antioxidants, mitoquinone and SKQ1, not vitamin C, mitigate doxorubicin-induced damage in H9c2 myoblast: pretreatment vs. co-treatment.
Ahmad, H; Barsotti, R; Chen, Q; Harvey, A; Martorana, R; Onal, H; Pjetergjoka, A; Prasad, S; Ross, E; Sacks, B; Sehgal, A; Wastella, C; Young, LH, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
plastoquinoneA polyprenylbenzoquinone that is 2,3-dimethylbenzoquinone with a polyprenyl side chain at position 5. There are several naturally-occurring plastoquinones with side chains of different length (containing between 6 and 9 isoprene units).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Photosynthetic carbon reduction014

Research

Studies (728)

TimeframeStudies, This Drug (%)All Drugs %
pre-199070 (9.62)18.7374
1990's80 (10.99)18.2507
2000's196 (26.92)29.6817
2010's326 (44.78)24.3611
2020's56 (7.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 49.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index49.95 (24.57)
Research Supply Index6.63 (2.92)
Research Growth Index4.86 (4.65)
Search Engine Demand Index83.44 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (49.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (0.40%)5.53%
Reviews69 (9.11%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other685 (90.49%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]